or Try an Advanced Search...

    Technical Analysis for PALI - Palisade Bio, Inc.

    Grade Last Price % Change Price Change
    D 4.82 4.56% 0.21
    PALI closed up 4.56 percent on Friday, May 31, 2024, on 1 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PALI trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New Downtrend Bearish 4.56%
    Wide Bands Range Expansion 4.56%
    Oversold Stochastic Weakness 4.56%
    Narrow Range Bar Range Contraction 6.87%
    Wide Bands Range Expansion 6.87%
    Down 3 Days in a Row Weakness 6.87%
    Older End-of-Day Signals for PALI ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Down 1% 1 day ago
    Rose Above Previous Day's High 1 day ago
    Up 3% 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    PALI Chart by TradingView
    Basic chart:

    Profile

    Palisade Bio, Inc. Description

    Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Surgery Abdominal Pain Gastrointestinal Tract Digestive System

    Is PALI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 21 Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
    May 14 Palisade Bio GAAP EPS of -$4.59
    May 14 Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
    May 7 Palisade Bio Appoints Margery Fischbein to its Board of Directors
    May 7 Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
    May 2 Palisade Bio looks to raise $4M in private placement
    May 2 Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
    May 1 Palisade Bio stock rallies 50% premarket on colitis drug update
    May 1 Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
    Apr 23 Dow Jumps Over 200 Points; US Services PMI Falls In April
    See more PALI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 36.6
    52 Week Low 3.82
    Average Volume 1,411,038
    200-Day Moving Average 7.73
    50-Day Moving Average 5.83
    20-Day Moving Average 6.08
    10-Day Moving Average 5.16
    Average True Range 0.66
    RSI (14) 38.27
    ADX 24.91
    +DI 24.49
    -DI 24.00
    Chandelier Exit (Long, 3 ATRs) 7.10
    Chandelier Exit (Short, 3 ATRs) 6.29
    Upper Bollinger Bands 8.35
    Lower Bollinger Band 3.82
    Percent B (%b) 0.22
    BandWidth 74.55
    MACD Line -0.42
    MACD Signal Line -0.22
    MACD Histogram -0.2017
    Fundamentals Value
    Market Cap 58.47 Million
    Num Shares 12.1 Million
    EPS 0.32
    Price-to-Earnings (P/E) Ratio 15.06
    Price-to-Sales 21.88
    Price-to-Book 0.39
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.22
    Resistance 3 (R3) 5.18 5.00 5.16
    Resistance 2 (R2) 5.00 4.90 5.02 5.13
    Resistance 1 (R1) 4.91 4.83 4.95 4.95 5.11
    Pivot Point 4.73 4.73 4.75 4.75 4.73
    Support 1 (S1) 4.64 4.63 4.69 4.69 4.53
    Support 2 (S2) 4.46 4.56 4.48 4.51
    Support 3 (S3) 4.37 4.46 4.48
    Support 4 (S4) 4.42